Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals’ EP-104IAR for the Treatment of Knee Osteoarthritis
— Publication ofEupraxia’s Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. — As outlined inLancet Rheumatology, Eupraxia’s EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportionate concentrations in plasma. — The U.S. Centers for […]